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Abstract: The increasing knowledge of the mechanisms involved in metabolism is shifting the
paradigms by which the pathophysiology of many pulmonary diseases is understood. Metabolic
dysfunction is recognized in obesity-associated asthma, but othermetabolic conditions have been
shown to be independently related to asthma. Novel insights have also recently been brought by
metabolomics in this filed. The purpose of this review is to discuss current perspectives regarding
metabolic dysfunction in asthma, from obesity-related asthma to other metabolic conditions and
the role of current pharmacological therapeutic strategies and lifestyle interventions. Obesity is
a well-recognized risk factor for asthma across the lifespan, which is generally associated with
poorer response to current available treatments, rendering a more severe, refractory disease
status. Besides the epidemiological and clinical link, untargeted metabolomics studies have
recently supported the obesity-associated asthma phenotype at the molecular level. Not only
obesity-related, but also other aspects of metabolic dysregulation can be independently linked to
asthma. These include hyperinsulinemia, dyslipidemia and hypertension, which need to be taken
into account, even in the non-obese patient. Untargeted metabolomics studies have further
highlighted several other metabolic pathways that can be altered in asthma, namely regarding
oxidative stress and systemic inflammation, and also suggesting the importance of microbiota in
asthma pathogenesis. Considering the reduced response to corticosteroids, other pharmacologic
treatments have been shown to be effective regardless of body mass index. Non-pharmacologic
treatments (namely weight reduction and dietary changes) may bring substantial benefit to the
asthmatic patient. Taken together, this evidence points towards the need to improve our knowl-
edge in this filed and, in particular, to address the influence of environmental factors in metabolic
dysfunction and asthma development. Personalized medicine is definitely needed to optimize
treatment, including a holistic view of the asthmatic patient in order to set accurate pharmaco-
logic therapy together with dietary, physical exercise and lifestyle interventions.
Keywords: asthma, diet, inflammation, metabolic, metabolomics, obesity
Introduction
The increasing knowledge of the mechanisms involved in metabolism is shifting the
paradigms by which the pathophysiology of many pulmonary diseases is
understood.1 Metabolic dysfunction is recognized in obesity-associated asthma,
although the underlying mechanisms are still not fully understood. Besides and
beyond obesity, other metabolic conditions that are part of the metabolic syndrome
(ie, a cluster of at least three conditions that occur together, including obesity,
increased blood pressure, high blood sugar and abnormal cholesterol or triglyceride
levels),2 have been shown to be independently related to asthma. These conditions
may contribute or even confound the epidemiological and clinical link of obesity
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and asthma. Novel insights have recently been brought by
metabolomics in this filed. The purpose of this review is to
discuss current perspectives regarding metabolic dysfunc-
tion in asthma, from obesity-related asthma to other meta-
bolic conditions and the role of current pharmacological
therapeutic strategies and lifestyle interventions.
Methods
The search for articles was carried out in MEDLINE data-
base to assess the link between metabolic dysfunction and
asthma using studies in English up to January 2020. The
search terms included were: “asthma” OR “wheezing” OR
“airway hyperreactivity” AND “metabolism” OR “meta-
bolic” OR “metabolomics”. The following terms were also
considered: “obesity”, “hypertension”, “diabetes”, “glu-
cose”, “insulin”, “hypercholesterolemia”, “cholesterol”,
“hypertriglyceridemia” and “triglyceride”. Original articles
and systematic reviews were included. The references of
these initial studies were hand searched and possibly eligible
studies were also included for review and discussion.
Literature Review and Discussion
Linking Obesity and Asthma
The association between obesity and asthma is firmly
established.3 In children, higher and faster weight gain is
associated with higher risks of preschool wheezing and
school-age asthma, as well as bronchial hyperresponsiveness
at school age and adolescence.4 In general, asthma prevalence
increases with children’s body mass index (BMI) percentile.5
This effect seems to occur very early in life, including during
pregnancy, as significant associations of maternal obesity,
gestational weight gain and asthma development in the off-
spring have been confirmed by meta-analysis.6 In adults, the
odds of developing asthma also increase with increasing
BMI,7 if BMI is over 30Kg/m2 in women, the risk of devel-
oping asthma rises by more than 2.5 fold.8
Besides the epidemiological link, obesity-associated
asthma has been recognized as a distinct clinical phenotype.
In early childhood, it may be characterized by increased dis-
ease severity and persistence, with lower response to
corticosteroids.9–11 The same features have also been
described in obese asthmatic adults, with increased healthcare
utilization and reduced quality of life.12 Typically, obesity-
associated asthma is defined as a late-onset non-type 2 pheno-
type. This is not specific to adults, asmany obese children with
asthma also have a predominance of the non-type 2
phenotype.13 However, a severe form of allergic, eosinophilic,
type 2 asthma has also been acknowledged to be associated
with obesity.14 Thus, obesity-associated asthma may be cur-
rently summarized into two forms, both associated with more
severe asthma: a) a late-onset non-type 2 phenotype (where
late-onset includes adults and older children); b) an early-onset
type 2 phenotype (perhaps a pre-existing asthma complicated
by obesity).15,16
Besides and Beyond Obesity: Metabolic
Conditions and Their Link to Asthma
Not only obesity but also other metabolic syndrome con-
ditions have been independently linked to asthma (Figure
1). The metabolic syndrome is not only associated with an
increased risk of heart disease, stroke and type 2 diabetes
but also with other low grade systemic inflammatory dis-
eases. A prospective cohort study including more than
23,000 adults has shown that a person with metabolic
syndrome has over 50% higher risk of asthma incidence
with an average of 11 years of follow-up.17 An increased
risk of asthma in the elderly has also been recently shown
in patients with metabolic syndrome, with a positive linear
association between the number of metabolic syndrome
components and the prevalence of asthma.18 However,
study results have been heterogeneous and metabolic syn-
drome per se was not an independent predictor of asthma
when BMI was adjusted.19 In fact, the recent study in the
elderly has shown that, among metabolic syndrome com-
ponents, abdominal obesity is most significantly related to
asthma.18 It must be considered though that metabolic
syndrome conditions interact (eg, hyperinsulinemia may
be a causal factor in the development of obesity),20 and
there may be a bias in the literature as many of these
studies analyzing asthma outcome were based on selected
cohorts of obese children and adults.5 The link between
these metabolic conditions and asthma may be important
to better understand the role of metabolic dysfunction in
asthma and ultimately to establish effective therapeutic
interventions. If obesity is indeed the phenotypic manifes-
tation of more comprehensive metabolic alterations that
may contribute to asthma development, any intervention
aimed at reducing weight without directly impacting these
metabolic pathways is likely to be only partially effective
in preventing and controlling asthma.21 In fact, in the
study by Park and col, the mediation analysis has sug-
gested that the metabolic syndrome is significantly asso-
ciated with asthma through insulin resistance and systemic
inflammation.18
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Insulin resistance can be broadly defined as an
impaired biologic response to insulin. This broad defini-
tion remains elusive as there is no generally accepted test
for insulin resistance. In clinical practice, insulin resis-
tance usually refers to a state in which a given concentra-
tion of insulin is associated with a subnormal glucose
response.22 Insulin resistance is associated with asthma
risk in children,23,24 and adults.25–27 It has been described,
in nondiabetic adults, as a risk factor for lower lung func-
tion or accelerated lung function decline, even when con-
trolled for BMI.28,29 Direct exposure of the airways to
insulin is associated with smooth muscle hypertrophy,
bronchial hyperresponsiveness and lung remodeling.30
Adults inhaling human insulin (now discontinued) may
exhibit cough, dyspnea, along with reductions in lung
function and diffusing capacity of the lung for carbon
monoxide.31 Insulin resistance may increase bronchial
reactivity through inhibition of presynaptic M2 muscarinic
receptors, while hyperinsulinemia may interfere with the
anti-inflammatory effects of insulin.32 It is also associated
with skeletal muscle weakness, including the respiratory
system,24 by reducing glucose utilization and inducing
abnormal fat metabolism in the muscle, which may impair
energy production in the mitochondria. In fact, excessive
weight gain in early life is associated with increased risk
of insulin resistance and asthma development during
school years.33 Similarly, both visceral fat accumulation
and insulin resistance have been associated with the devel-
opment of asthma in type 2 diabetic adults.27
Dyslipidemia and hypertension are also risk factors for
lower lung function or accelerated lung function
decline.34,35 In the study by Park and col low high density
lipoprotein cholesterol has been associated with asthma in
the elderly.18 Higher prevalence of asthma has been found
in children with high serum cholesterol and triglyceride
levels.5,36,37 Asthma and hypertension coincide more fre-
quently than expected by chance. Its comorbidity with
asthma persists after consideration of excessive weight,
smoking and use of specific drugs (including non-
selective beta-blockers and systemic corticosteroids),
although it becomes weaker.38,39 There are several shared
genes associated with asthma and hypertension that form
modules on interaction networks, suggesting that this
comorbidity could be at least partly explained by concor-
dantly altered genetic regulation.39,40 Another possible
explanation relates to medication side effects, particularly
the use of non-selective beta-blockers.39 Interestingly,
lower doses of inhaled corticosteroids (ICS) may confer
a “protective” association, while the opposite is applicable
for higher doses of inhaled or systemic
corticosteroids.39,41,42 This may suggest that adequate con-
trol of lower airway inflammation at appropriate doses of
ICS may attenuate cardiovascular risk.
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Figure 1 Schematic representation of the metabolic syndrome-asthma link.
Notes: Not only obesity-related but also other aspects of metabolic dysregulation can be independently linked to asthma, including dyslipidemia, hypertension and insulin
resistance. Most commonly recognized mechanisms linking metabolic syndrome conditions and asthma involve inflammation and airway hyperreactivity. Metabolic syndrome
conditions are associated in a complex multidirectional network and their link with asthma development or progression generally depends on the composite interaction
between host genetics, diet and other exposures (environmental, medication, etc), physical activity and microbiota.”
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Thus, hyperinsulinemia, dyslipidemia and hypertension
need to be considered as they may also be associated with
asthma development or progression. Furthermore, this may
contribute or even confound the epidemiologic link
between asthma and obesity.5 Children whose weight is
within or even below the healthy range may still be more
susceptible to develop asthma because of metabolic
derangements.5 In fact, children with diagnosed asthma
tend to have higher serum triglyceride levels and higher
rates of insulin resistance. These associations are indepen-
dent of gender, tobacco smoke exposure and BMI.5
Inflammation is a common feature in most studies addres-
sing metabolic dysfunction in asthma. Asthma is
a heterogeneous disease that is usually characterized by
chronic airway inflammation. However, there is increasing
appreciation of asthma as a systemic disease. Inflammation
is not restricted to the airways, with profound cross-
communication with other organs at distance through inflam-
matorymediators. In obesity-associated asthma, adipose tissue
increases pro-inflammatory cytokines that lead to systemic
inflammation since very early in life. Dietary imbalances
with caloric excess and the resultant metabolic-associated
inflammation profoundly affect the immune system.5 A non-
type 2 mechanism that comprises the NLRP3 inflammasome
has been described. Mice fed with hypercaloric diet develop
airway hyperreactivity independent of adaptive immunity but
dependent on NLRP3 (just as it appears to regulate type 2
diabetes) and interleukin (IL)-17A produced primarily by type
3 innate lymphoid cells.16,43 Considering this pathway, a role
for brodalumab (anti-IL-17RA) has been suggested in obesity-
associated asthma, which has not been yet explored.
An increase in IL-6, tumor necrosis factor (TNF)-alfa
and leptin has also been described in obese asthmatic
patients (versus healthy controls and versus non-obese
asthmatic patients), linked to macrophage proliferation
and differentiation in the lung tissue.44 IL-6, a biomarker
of systemic inflammation and metabolic dysfunction (posi-
tive associations with BMI, hypertension and diabetes), is
associated with severe asthma in obese and non-obese
patients. In particular, significantly higher IL-6 levels
were found in asthmatics with worse lung function and
more frequent asthma exacerbations.45 Persistently ele-
vated TNF-alfa in supernatants of lipopolysaccharide-
stimulated peripheral blood mononuclear cells at birth
and three months in offspring of mothers with excessive
gestational weight gain is described associated with sub-
sequent asthma development.46 Furthermore, adiponectin
is decreased in obesity, a mediator that is able to reduce
airway inflammation.47 Lower levels of anti-oxidants have
been described in asthmatics.48 Obesity has also been
associated with an increase in systemic oxidative stress,
further contributing to a pathological imbalance.49
Beyond obesity, both dyslipidemia and hyperinsuline-
mia per se can influence innate and adaptive defense
mechanisms in the respiratory tract, with proinflammatory
cytokines and chemokines production and increased bron-
chial tone.5
An Innovative View: Inputs from
Metabolomics in Asthma
Metabolomics has provided unique and novel insights into
asthmaprofiling at themolecular level. In particular, composite
signatures in untargeted studies have brought innovation into
the field of metabolic dysfunction in asthma.50 This opens the
possibility of having distinct biomarkers, which may better
reflect the complexity and dynamics of genome-
environmental interaction networks in asthma and even out-
match single or biomarker panels in asthma diagnosis and
management. It also opens the possibility of new treatment
targets and personalized care in asthma treatment and
prevention.50
Distinct metabolic signatures have been found in asthma,
unrelated to obesity and other metabolic syndrome conditions.
Currently, several clinical studies using untargeted metabolo-
mics approaches have yielded distinct results and suggested
a broad number of metabolites associated with asthma.
Common altered individual metabolites identified by different
research groups include amino acids, lipids, purines, salts and
alcohols (Table 1). More interestingly, these studies suggest
that several metabolic pathways are altered in asthma. This
preliminary data supports that further insights can contribute to
increased knowledge in asthma. In particular, there is consid-
erable consistency in identifying amino acids metabolism as
significant. Amino acids can have antioxidant functions; in
particular glycine, glutamine and glutamate may have poten-
tially protective effects, whereas phenylalanine can have
adverse effects.51 Oxidative stress has a significant role in
asthma pathophysiology and lung damage.52 Oxidized com-
pounds that significantly distinguish asthmatics from healthy
subjects have been identified in untargeted metabolomics
studies.53 Metabolic pathways associated with oxidative stress
in asthma involve not only amino acids, including essential
components in glutathione metabolism, but also lipids
peroxidation.54 Furthermore, the influence of the microbiome
on asthma pathogenesis has recently gainedmuch interest with
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novel evidence being added, namely regarding short chain
fatty acids produced by intestinal microbiota and its role in
oxidative stress and inflammation.55 Changes in the energy
metabolism with increased tricarboxylic acid-cycle metabo-
lism have been associated with an enhanced requirement for
energy in asthma exacerbations and uncontrolled asthma, with
a more hypoxic, acidic and oxidizing environment. In this
setting, purine metabolism has also been identified in untar-
geted metabolomics studies in humans. Although adenosine is
well known for its bronchoconstrictor and inflammatory
effects, not only adenosine but also other related molecules
have been detected as significantly altered in asthma, including
deoxyadenosine, adenosine monophosphate and inosine.56–58
Finally, metabolites related to the epigenetic pathways have
also been reported.58,59 In particular, epigenetic methylation
has been suggested to skew immune responses towards a type
2 inflammation phenotype.60–62
Metabolomics also supports obesity-associated asthma
phenotype at the molecular level. In this field, distinct
respiratory and urinary metabolic profiles have been
Table 1 Metabolites Associated with Asthma in at Least Two Independent Studies in Humans Comparing Untargeted Metabolomics





















































































Notes: *Classification according to the human metabolome database.117 ↑ - higher levels reported in asthmatics (versus healthy subjects); ↓ - lower levels reported in
asthmatics (versus healthy subjects); #variable results according to EBC collecting temperature.
Abbreviations: EBC, exhaled breath condensate; MS, mass spectrometry; NMR, nuclear magnetic resonance.
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reported in obese and non-obese asthmatics, supporting
not only a unique phenotype but also unique pathophysio-
logic mechanisms.63–65 The identified specific biomarkers
are involved in energy metabolism (methane) and carbo-
hydrate metabolism (pyruvate and glyoxylate and dicar-
boxylate metabolic pathways). An association between
exhaled methane due to excessive colonization of the
gastrointestinal tract with methanogen archaea and greater
BMI and body fat percentage has been reported.66,67
Furthermore, subjects with increased methane production
might present with alteration in glucose metabolism and
altered glycemic control.68 Likewise, the pyruvate path-
way is the sum of all biochemical reactions involving
pyruvate and is at the intersection of pathways important
for glucose and energy homeostasis. Furthermore, the
alteration of glyoxylate and dicarboxylate metabolism in
aged human female subjects has been related to mitochon-
drial dysfunction that would result in decreased ability to
detoxify reactive oxygen species.69 These are examples of
how these untargeted metabolic studies combining high
throughput technologies with bioinformatics can bring
totally innovative views, which are complementary to our
previous knowledge on the disease and its mechanisms.
Current Therapeutic Interventions:
Where Do We Stand?
Currently, the pharmacologic treatment of asthma relies on
ICS (or ICS–long-acting beta2-agonists associations) as the
main preferred therapeutic controller option. Although this
strategy is effective for many asthma patients, not all patients
are controlled and no cure/long-lasting effect can be assured.
Treating an obese-asthmatic patient is often more challenging
as obese and overweight asthma patients tend to have poorly
controlled asthma that does not respond as well to controller
therapy with ICS compared to normal-weight patients.3
However, it is likely that individual responses to therapy
may vary significantly according to the predominant airway
inflammation pattern in obesity-associated asthma, namely
type 2 or non-type 2 involved mechanisms. Contrary to ICS,
the response to montelukast does not seem to be affected by
BMI,70 although it is acknowledged that this drug is generally
less effective than ICS, even in obese asthmatics.71,72 Of note,
tiotropium, a drug pointed as a controller therapy in step 4/5 in
asthma, leads to improvements in asthma control, exacerba-
tions and lung function that have been reported to be indepen-
dent of BMI.73 The predominance of neutrophilic airway
inflammation may correlate with better response to tiotropium
in asthmatics,74 which may thus particularly benefit some
obese patients with non-type 2 asthma.
Regarding the currently available biologic treatments
approved for asthma, the anti-immunoglobulin E (IgE) anti-
body omalizumab has significantly reduced asthma exacerba-
tions and improved asthma control in obese patients with
severe allergic persistent asthma,75 but obesity may reduce
the effectiveness of this monoclonal antibody.76 Interestingly,
a supervised cluster analysis has suggested that the subgroup
of asthmatic patients that benefited the most from the more
recently approved anti-IL-5 monoclonal antibody mepolizu-
mab is characterized by raised blood eosinophils, obesity and
a mean duration of disease of 18 years, which could thus
represent the early-onset type 2 obese-asthmatic patients.77
A recent meta-analysis has shown, however, that a fixed
dose of mepolizumab reduces exacerbations in patients with
severe eosinophilic asthma, irrespective of body weight/
BMI.78 Contrary to fixed doses, the anti-IL-5 antibody resli-
zumab is dosed according to body weight. Thus, patients with
obesity may require higher doses. Similarly to mepolizumab,
for patients with severe, uncontrolled eosinophilic asthma,
recent evidence shows that fixed doses of anti-IL5R benrali-
zumab also decrease asthma exacerbations and increase lung
function regardless of BMI value, but improvements, particu-
larly in lung function, may be less robust for obese patients.79
Finally, it has been recently suggested that dupilumab (anti-IL
-4RA) reduces severe exacerbations and improves lung func-
tion in patients with uncontrolled, moderate-to-severe asthma,
regardless of BMI.80 Besides reduced asthma exacerbation
rates and improved lung function, several clinical controlled
trials show that these biological therapies allow reductions in
corticosteroids use. However, a recent study on factors asso-
ciated with omalizumab response suggested that obesity (ver-
sus normal weight) is a determinant condition for unchanged/
increased level of concomitant asthma medication.76 This has
not been confirmed by others.75 Data comparing regular corti-
costeroid-sparing effect of all available monoclonal antibodies
in obese versus non-obese severe asthmatics is lacking.
Nevertheless, these therapeutic interventions are particularly
important to avoid the burden of systemic corticosteroids,
namely in asthma exacerbations, which may overall reduce
inflammation but have profoundmetabolic adverse effects and
therefore a very significant unfavorable risk-benefit ratio.
The potential role for other medications that modify
metabolic syndrome conditions to serve as therapeutic
options for asthma has been recognized. The peroxisome
proliferator-activated receptors (PPAR) were initially recog-
nized for their functions in lipid regulation and glucose
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metabolism but accumulating experimental findings support
their anti-inflammatory properties and potential clinical ben-
efits of PPAR-gamma agonists in the treatment of asthma.81
However, these drugs efficacy remains controversial and
larger randomized clinical trials (RCTs) are lacking. PPAR-
gamma agonists are also associated with important side
effects, which may be possibly minimized by administration
via inhalation rather than systemic delivery, or through com-
bination of drugs at lower concentrations.81 Likewise, the
metabolic and immunomodulatory properties of statins, tra-
ditionally used to manage cholesterol levels, have led to
several studies evaluating its role for the treatment of asthma.
Epidemiological and observational studies pointed towards
therapeutic benefits in asthma, but RCTs using oral statins
yielded conflicting results.82–84 RCTs in severe asthma are
lacking and studies using statins delivered by inhalation are
alsowarranted.84 Evidence of clinical benefit of metformin in
asthma is also growing,85–87 although it has seldom been
investigated in real-life clinical settings. In particular,
a decrease in asthma exacerbations in response to metformin
has been reported in different populations.88,89 This warrants
further investigation. Future research may also address
whether the effects of metformin are limited to patients
with diabetes or whether it could bring advantage also in
case of obesity, insulin resistance or the metabolic syndrome.
Currently, the role of these and other pharmacological stra-
tegies addressing metabolic syndrome conditions in asthma
needs appropriate study design and careful analysis to avoid
biases and allow successful results to the individual patient.
Complementary to medication, non-pharmacological
interventions have an important role in asthma management.
In general, weight loss (both non-surgically and surgically)
improves a number of clinical asthma outcomes in obese
patients.3,90-92 Weight reduction in obese asthmatics improves
asthma control, quality of life and airway hyperreactivity,93–95
but may have more limited effects in early-onset disease with
high IgE levels,93,96 and in patients with metabolic
syndrome.97 Bariatric surgery does not reduce airway eosino-
philia, even when symptoms and airway hyperreactivity
improve.93 On the contrary, increased airway lymphocyte
counts and peripheral blood lymphocyte function have been
reported after the surgery, unrelated to airway
hyperreactivity.93 Other biomarkers of systemic and pulmon-
ary inflammation, such as blood C-reactive protein, blood IL-6
or sputum TNF-alpha decrease after surgery.95,98 Bariatric
surgery also decreases leptin and increases adiponectin
levels.98–100 Overall, weight loss is associated with improve-
ment in global health status and quality of life in obese
patients, and even a 5% to 10% weight loss may produce
significant improvements in asthma control.101 Weight reduc-
tion may improve asthma control through mechanical unload-
ing the respiratory system or reduced inflammation, but
changes in dietary composition and lifestyle, including exer-
cise, must be also considered.101 In fact, the role of diet cannot
be underestimated. A dietary pattern of high red and processed
meats, fats and fried foods, that is low in fiber and high in
sugar is associated with low lung function and increased
respiratory symptoms, even when controlled for BMI.102,103
Changing dietary quality can be effective for improving
asthma control in obese and non-obese patients.101 In particu-
lar, both dietary fiber composition and gut microbiota popula-
tion influence the production of short-chain fatty acids, which
can change airway inflammation. Most of these observations
have been elegantly shown in mice, suggesting dietary fiber
effects as early as during in utero development. However,
there are only very few controlled trials in this field, and the
same holds true for low-fat diet.101 A diet high in fruits and
vegetables or Mediterranean diet has been associated with
improved asthma control and asthma quality of life, although
the studies are rather small and heterogeneous.104–106
Dietary intervention studies are often included in more
general lifestyle interventions. Physical exercise can also
improve symptoms and asthma control, especially when
combined with dietary intervention.3,101 Although lifestyle
interventions are complex and implementation challenging,
these approaches may bring substantial benefit to asthma
patients, given the fundamental role of environmental expo-
sures. Of note, it is not just obese patients who seem to
benefit from improved dietary quality and exercise.101
Another potential approach is to modify the micro-
biome to prevent and treat asthma. Microbiota changes
have been pointed in the early development of asthma.21
However, specific advice on the most effective regimes
cannot yet be given, considering the high heterogeneity
between the studies and low quality of evidence.107−109
Taken together, these interventions will likely be more
effective if combined.
Conclusion
Current evidence has largely expanded our view on meta-
bolic dysfunction and asthma. Obesity is a well-recognized
risk factor for asthma across the lifespan, which is gener-
ally associated with poorer response to current available
treatments, rendering a more severe, refractory disease
status. However, not only obesity-related, but also other
aspects of metabolic dysregulation may be independently
Dovepress Pite et al
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linked to asthma. These include hyperinsulinemia, dysli-
pidemia and hypertension, which need to be taken into
account, even in the non-obese patient. The recent untar-
geted metabolomics studies bring additional novel
insights, supporting an obesity-associated asthma pheno-
type at the molecular level. They also highlight several
other metabolic pathways that can be altered in asthma,
likely associated with systemic inflammation. Taken
together, this evidence points towards the need to improve
our knowledge in this filed and, in particular, to address
the importance of environmental factors in metabolic dys-
function and asthma development. Personalized therapeu-
tic approaches are definitely needed that comprise not only
classical pharmacological treatments but also more pro-
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